LuciEna 50 mg Tablet

Description

LuciEna (Enasidinib) is a targeted therapeutic solution designed specifically for adults battling relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase 2 (IDH2) mutation. As an isocitrate dehydrogenase-2 inhibitor, LuciEna works by precisely targeting the underlying genetic mutation, offering a new avenue of hope for patients seeking effective treatment. With a recommended dosage of 100 mg taken orally once daily, LuciEna can be administered with or without food, providing flexibility to fit into your daily routine. It's important to swallow the tablet whole without chewing or crushing, ensuring optimal efficacy as you embark on your treatment journey. LuciEna stands out not only for its innovative approach but also for its commitment to improving patient outcomes. Experience the potential of targeted therapy and take a significant step towards managing your AML with LuciEna Enasidinib 50 mg Tablets.